NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 29 March 2010 Intravenous cangrelor has failed to show a benefit on the primary end point of a composite of death, myocardial infarction (MI) or ischaemia-driven revascularisation 48 hours […]
Category Archives: New medicines
NPC Archive Item: Cladribine – another potential new oral treatment for MS?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 March 2010 Oral cladribine, given as one of two cumulative doses (either 3.5mg or 5.25mg/kg) in short courses, was more effective at preventing relapse than placebo in the […]
NPC Archive Item: Fingolimod – a potential new oral treatment for multiple sclerosis?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 March 2010 Data from the 24 month FREEDOMS trial has shown that fingolimod, a once daily, oral drug for the treatment of relapsing-remitting multiple sclerosis (RRMS), was more […]
NPC Archive Item: NICE publishes guidance on certolizumab pegol▼ for the treatment of rheumatoid arthritis
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 17 March 2010 NICE has published guidance (TA 186) recommending certolizumab pegol▼ as an option for the treatment of adults with rheumatoid arthritis (RA) only if: the drug is […]
NPC Archive Item: Liraglutide▼ for the treatment of obesity
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 04 March 2010 Obese, non-diabetic patients received one of four doses of liraglutide▼ subcutaneously once a day versus open-label orlistat orally three times a day in a European, phase […]
NPC Archive Item: One-year follow up data for bivalirudin▼ in patients with high-risk STEMI
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25 February 2010 The HORIZONS-AMI trial assessed high-risk patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). One year follow-up data to this study suggest […]
NPC Archive Item: Dabigatran etexilate▼ is as effective as warfarin for the short term management of acute venous thromboembolism
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 3 February 2010 In the RE-COVER trial (n=2,564), dabigatran etexilate▼ 150mg twice daily for six months was found to be as effective as dose-adjusted warfarin in preventing recurrent venous […]
NPC Archive Item: Apixaban vs. enoxaparin as thromboprophylaxis in knee replacement surgery
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22 January 2010 In a non-inferiority design, ADVANCE-1 found that results for oral apixaban were similar to s.c. LMWH enoxaparin 30 mg twice daily (not non-inferior) for a primary […]
NPC Archive Item: Earlier access to new medicines
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 15 January 2010 Summary: A report, describing the key elements of a scheme to make available certain new medicines before they are formally licensed, has been produced by a […]
NPC Archive Item: Consultation on proposed ‘Innovation Pass’
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11 December 2009 The Department of Health (DH) has launched a consultation on the Government’s proposals for an ‘Innovation Pass’ pilot. The aim of which is to make selected […]